Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY Gynecologic Oncology Reports Pub Date : 2024-07-13 DOI:10.1016/j.gore.2024.101459

Michelle Greenman , Stefania Bellone , Cem Demirkiran , Tobias Max Philipp Hartwich , Alessandro D. Santin

{"title":"Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer","authors":"Michelle Greenman , Stefania Bellone , Cem Demirkiran , Tobias Max Philipp Hartwich , Alessandro D. Santin","doi":"10.1016/j.gore.2024.101459","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options for recurrent disease are an unmet need.</p></div><div><h3>Case</h3><p>A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment. Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to baseline. Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment. The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions.</p></div><div><h3>Conclusion</h3><p>Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy. Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients are currently ongoing (<span>https://classic.clinicaltrials.gov/ct2/show/NCT06028932</span><svg><path></path></svg>).</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001383/pdfft?md5=ba3b131e3649832a3482457536d43899&pid=1-s2.0-S2352578924001383-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578924001383","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options for recurrent disease are an unmet need.

Case

A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment. Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to baseline. Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment. The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions.

Conclusion

Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy. Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients are currently ongoing (https://classic.clinicaltrials.gov/ct2/show/NCT06028932).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

萨妥珠单抗戈维替康治疗重度铂类耐药的高级别浆液性卵巢癌

背景复发性铂耐药高级别浆液性卵巢癌（HGSOC）的治疗仍是一项挑战。病例一位69岁的患者患有复发性、转移性、铂类耐药、TROP2过表达的HGSOC，在多次化疗和靶向治疗失败后，她对抗体药物共轭物（ADC）sacituzumab govitecan产生了明显反应。在接受了sacituzumab govitecan治疗后，她的部分反应得到了证实，CA-125也恢复到了基线水平。目前她已经完成了8个周期的治疗（即超过6个月的治疗时间），她的病情继续对萨库珠单抗-戈维替康治疗产生反应。ADC的耐受性很好，剂量为10 mg/kg，没有剂量限制性毒性，也不需要减少剂量。萨库珠单抗-戈维替康治疗铂类耐药卵巢癌患者的临床试验目前正在进行中 (https://classic.clinicaltrials.gov/ct2/show/NCT06028932)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.